Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 3 Trial
Boehringer Ingelheim has announced positive topline results from its phase III SYNCHRONIZE-1 clinical trial for survodutide, an investigational dual glucagon/GLP-1 receptor agonist. The study demonstrated that adults with obesity or overweight, excluding those with type 2 diabetes, achieved an average body weight reduction of 16.6% after 76 weeks, significantly outperforming the 3.2% reduction seen in the placebo group. The trial successfully met both co-primary endpoints, with 85.1% of participants on survodutide achieving at least a 5% weight loss compared to 38.8% on placebo. Analysis indicated that weight loss primarily resulted from fat tissue reduction, accompanied by significant decreases in waist circumference, a key marker for cardiometabolic risk. Safety profiles were consistent with the GLP-1 class, showing mild to moderate gastrointestinal events without new safety concerns. Company executives and investigators highlighted the drug's potential to address obesity and related metabolic conditions, including liver disease. As an unapproved investigational therapy, survodutide awaits further phase 3 data expected in 2026, positioning it as a promising candidate in the growing market for metabolic health treatments.
Wire timeline
Boehringer Ingelheim's Survodutide Achieves 16.6% Weight Loss in Phase 3 Trial
Boehringer Ingelheim has announced positive topline results from its phase III SYNCHRONIZE-1 clinical trial for survodutide, an investigational dual glucagon/GLP-1 receptor agonist. The study demonstrated that adults with obesity or overweight, excluding those with type 2 diabetes, achieved an average body weight reduction of 16.6% after 76 weeks, significantly outperforming the 3.2% reduction seen in the placebo group. The trial successfully met both co-primary endpoints, with 85.1% of participants on survodutide achieving at least a 5% weight loss compared to 38.8% on placebo. Analysis indicated that weight loss primarily resulted from fat tissue reduction, accompanied by significant decreases in waist circumference, a key marker for cardiometabolic risk. Safety profiles were consistent with the GLP-1 class, showing mild to moderate gastrointestinal events without new safety concerns. Company executives and investigators highlighted the drug's potential to address obesity and related metabolic conditions, including liver disease. As an unapproved investigational therapy, survodutide awaits further phase 3 data expected in 2026, positioning it as a promising candidate in the growing market for metabolic health treatments.
PharmaTimes